STAT3 and neoplasm: Depending on the pathway, these drugs can upregulate the expression of PD-L1 by activating different signaling pathways (such as RAS/RAF, PI3K/AKT, JAK/STAT3) and release specific immunosuppressive cytokines, thus weakening the anti-tumor immune response.